For informational and educational purposes only. BPC-157 is for in-vitro research use only. Not for human or animal use. Not medical advice.
GLP-1 receptor agonists have become some of the most heavily studied compounds in metabolic biology research. Semaglutide, a GLP-1 receptor agonist, and Tirzepatide, a dual GIP/GLP-1 receptor agonist, represent two of the most prominent research compounds in this class.
Semaglutide is a GLP-1 receptor agonist with approximately 94% homology to native GLP-1. Its enhanced half-life compared to native GLP-1 makes it particularly interesting for research applications requiring sustained receptor engagement studies.
Tirzepatide’s dual mechanism — acting on both GLP-1 and GIP receptors — has made it the subject of considerable research interest, particularly in metabolic biology studies examining the combined effects of these two incretin pathways.